OR WAIT null SECS
Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
There is not currently an FDA approved treatment for NASH.
With no US Food and Drug Administration (FDA) approved treatments for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), more long-term studies on the liver diseases are warranted.
In recent years, researchers have begun a massive undertaking in learning how NASH patients are being cared for in the TARGET-NASH study.
TARGET-NASH is an observational study of participants with NAFLD and/or NASH in usual clinical practice and is part of a series of Target studies targeted several diseases, including inflammatory bowel disease and asthma.
One of the reasons researchers have not had much success in developing a treatment for NASH or NAFLD is the heterogenous nature of the conditions.
In an interview with HCPLive®, A. Sidney Barritt IV, MD, MSCR, Associate Professor of Medicine, Division of Gastroenterology and Hepatology, Director, UNC Liver Center, said a goal of the study will be to improve care for this patient population in an effort to develop suitable treatments.
Barritt said there are currently more than 5000 patients enrolled from both academic centers and community centers in the trial since enrollment began in 2016.
The goal of the ongoing study is to get an unbiased view of the disease moving forward.